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lmmunocontraceptive Vaccines for Control of
Fertility in the European Red Fox (Vulpes vulpes)
Mark P. Bradley

Abstract: This paper describes the strategies being
employed in the development of an immunocontraceptive
vaccine using sperm antigens, to control fox populations in
Australia. It is proposed that such a vaccine will be
delivered orally in a bait, thereby ultimately stimulating a
mucosal immune response within the female reproductive
tract. The eventual success in producing such a vaccine

requires the identification of gamete antigens that cause
immunological infertility, a detailed understanding of the
reproductive immunology of foxes, and the selection of the
most effective form of antigen delivery system.
Keywords: Sperm antigens, immunocontraception,
mucosal immunity

Introduction
lmmunocontraception potentially offers the most
effective method for the management and long-term
population control of vertebrate pest species. The
idea of using fertility control for such purposes is not
new. In the early 1960's, a number of investigators
examined the use of chemical sterilants to limit the
reproductive capacity of animal populations (Linhart
1964). None of these methods proved effective,
probably because these chemicals lead to castration
of the target species. Castration removes the source
of the key sex hormones, and this effect has the
potential to interfere with the normal social structure of
a target population, an undesirable outcome that could
lead to a breakdown in established social hierarchies
and may result in compensatory breeding.

lmmunocontraception for Feral Species
In 1992, the Cooperative Research Centre for the
Biological Control of Vertebrate Pest Populations was
established in Australia to explore alternative methods
of fertility control based on the use of gamete antigens
as immunogens. One of the species being targeted in
this research is the European red fox (Vulpes), which
is a major vertebrate pest in Australian responsible for
the loss of many native species through predation.
Our approach to immunocontraceptive control of
the fox involves developing a bait-delivered oral
vaccine. In this paper, I will discuss the experimental
approaches used in the development of such a
vaccine for foxes. Specifically, the focus will be on the
identification of sperm antigens as vaccine candidates,
the immunological questions that need to be addressed,
and the development of appropriate delivery systems.

Although these considerations are directed
toward an application for the fox, many of the concepts are relevant for immunocontraception in other
species. The wider concerns relating to species
specificity, and the use of recombinant vaccines, will
be covered in the paper by Tyndale-Biscoe in this
proceedings.

Components of an lmmunocontraceptive
Vaccine for Feral Species
A successful contraceptive vaccine should (1) block
fertilization or early embryonic development; (2) affect
both sexes; (3) be species specific; (4) provoke a
prolonged and sustained immune response; and
(5) not interfere with the normal social function of the
animal. In particular, an effective mechanism for
transmitting the vaccine throughout the target population must be found. This mechanism must be cost
effective to manufacture and administer and must not
impose hazards to the environment. These caveats
make the development of an immunocontraceptive
vaccine for wild animals highly challenging.

Reproductive Studies
Sperm Antigens as Targets for
lmmunocontraception
Vaccines developed toward sperm antigens would
probably be capable of inducing infertility in both
males and females. Potentially, this characteristic has
the advantages not only of rendering sperm within the
male genital tract incapable of fertilization before entry
into the female but also of inactivating sperm within
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the female genital tract. The direct immunization of
males and females with extracts of sperm or testis
results in a significant inhibition of fertility (Menge and
Naz 1988).
We have tested the antifertility effect of antibodies to sperm in a group of six female foxes (Bradley
1994). Necropsy results revealed that there were
21 ovulations in this group of foxes. In all females
examined, no live fetuses were found; 13 of 21
oocytes had been fertilized and embryos implanted,
but all failed as determined by the presence of embryonic resorption scars. Examination of uterine flushes
failed to find any unfertilized or preimplantation
embryos. It was concluded that immunization with
sperm results in an immunological block to fertility and
that sperm immunization has two effects, one at the
embryonic level and the other during fertilization.
The results of this experiment are consistent with
those previously reported on the effect of experimentally induced sperm antibodies on fertility (O'Rand
1977, Koyama et al. 1984). Many of these experiments found that anti-sperm antibodies appeared to
exert their effect on fertility not at the level of fertilization but rather at later stages ranging from early
blastocyst development to implantation (Menge and
Naz 1988), suggesting that some antigens are shared
between the sperm and the embryo. Immunization
against such complex mixtures of antigens is not really
a practical approach for vaccine development. Instead,
the individual antigenic components capable of
causing immunological contraception need to be
identified. Indeed, a number of specific sperm proteins can impair fertility when used to immunize
animals (Naz 1987, LeVan and Goldberg 1990).
The most common approach to sperm antigen
identification and selection is the use of monoclonal
antibodies to sperm protein of the species under study
(Anderson et al. 1987). One of the best examples is
the PH-20 protein originally identified with monoclonal
antibodies to guinea pig sperm. Fertility trials have
shown that male and female guinea pigs immunized
with PH-20 become infertile (Primakoff et al. 1988).
More recently, the PH-20 genes from a number of
other species have been cloned, leading to the

possibility that this antigen may have applicability as a
vaccine target in other species.
Another sperm antigen of interest is SP-10. This
has been designated as a "primary vaccine candidate"
by the World Health Organization Task Force on
Contraceptive Vaccines (Herr et al. 1990a and b).
Antibodies to SP-10 inhibit the penetration of hamster
eggs by human sperm, and trials in baboons currently
in progress will assess the applicability of this antigen
as an immunocontraceptive for humans. Recently, a
homologue of SP-10 (called MSA-63) has been
identified in the mouse and cloned (Liu et al. 1990).
Furthermore, antibodies to MSA-63 have been shown
to have a strong inhibitory effect on the in vitro fertilization of mouse ova, providing good support that this
class of antigens is worthy of study as potential
targets for immunocontraception.

Fox Sperm Antigens Currently
Being Assessed for Use in an
lmmunocontraceptive Vaccine
A number of monoclonal antibodies have been developed to fox sperm antigens and used to clone the
cognate genes from a fox testis cDNA library. One of
these candidate antigens, FSA-lr, has been through
fertility trial testing and found to have no effect on
fertility. Other antigens are currently in the fertility trial
phase of assessment.

Fox Acr. 1 (Acrosomal Protein 1 )
The FSA-Acr.1 protein is located within the acrosomal
matrix of fox sperm, and it is first detected during
spermatogenesis on the developing acrosome of
round and elongating spermatids (Beaton et al. 1995).
A monoclonal antibody to FSA-Acr.1 (FSA-10) was
used to screen a fox testis cDNA library, and a cDNA
clone was isolated. Database searches with the
deduced amino acid sequence of FSA-Acr.1 revealed
that the clone has high homology to both human and
baboon sperm protein SP-10 and the mouse sperm
protein, MSA-63. The region of highest homology is
within the carboxyl terminus. Within the central
portion of the open reading frame, the fox sequence
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contains amino acid motifs that are absent from both
the human and baboon SP-10 and mouse MSA-63
sequences. We have expressed the FSA-Acr.1
protein in vitro, and this protein is being assessed in
fertility trials to determine whether or not antibodies to
FSA-Acr.1 can impair fertility.

Fox LDH-C,
Lactate dehydrogenase C, (LDH-C,) is an intracellular
sperm-specific enzyme a portion of which is located
on the sperm flagella plasma membrane. A number of
studies have previously demonstrated that, when
purified LDH-C, is used to immunize either mice,
rabbits, or baboons, fertility was reduced by 60 to 80
percent (LeVan and Goldberg 1990). Epitope mapping studies of mouse and human LDH-C, have
identified an antigenic peptide within the N-terminal
region of the open reading frame, from amino acids
5-19 (Millan et al. 1987). This sequence also has the
greatest variation in sequence between different
species. We have recently cloned a fox LDH-C, cDNA
and have derived sequence information from the 5'
region of the open reading frame. This research has
enabled us to synthesize a peptide to this region that
was subsequently conjugated to the tetanus toxoid
protein as an immunogenic carrier protein. This
peptide-protein conjugate has been used to immunize
female foxes by the intra-Peyers' patch route, and the
immune responses and the effects of this immunization on fox fertility are currently being measured.

Cloning of the guinea pig PH-20 revealed that it has
homology at the protein level with bee venom
hylauronidase (Gmachl and Kreil 1993). Hylauronidase
enzymatic activity is present within the head of mammalian sperm, and it has been shown that PH-20 has
hylauronidase enzymatic activity (Gmachl et al. 1993).
We have isolated a cDNA from a fox testis cDNA
library encoding PH-20, and partial sequence analysis
indicates close homology to PH-20 antigens cloned
from other species. The antifertility effects in foxes of
PH-20 immunization will be assessed with the whole
protein and with selected peptide sequences.

Production of Recombinant Antigens
The in vivo testing of candidate antigens requires the
large-scale production of recombinant proteins. A
number of commercially available protein expression
systems exist for this purpose; however, the selection
of the system for a particular purpose eventually
depends on the properties of the antigen under study.
For example, is the protein highly glycosylated, and
how important is this for antigenicity? Or, is the
protein composed of multiple subunits? These
considerations all have bearing on the success and
selection of any one expression system. We have
extensively used the maltose binding protein (MBP)
expression system for the production of recombinant
sperm proteins. This system produces a fusion of
MBP to the protein of interest. Following expression,
the fusion product is purified by affinity chromatography to yield a hybrid protein. The MBP can be
cleaved and purified from the target protein, but this
has some drawbacks in that small amounts of MBP
still contaminate the antigen preparations, and loss of
antigen occurs at each purification step. Unfortunately, the selection of expression systems for production of recombinant proteins is still something of a
trial-and-error procedure, and several systems may
have to be evaluated before selection of one that suits
the purpose of the antigen under study.

In Vivo Fertility Testing of Recombinant
Sperm Antigens
Ideally, during the selection of monoclonal antibodies
that identify candidate sperm vaccine antigens, part of
the testing procedure should include the use of
functional assay to determine the effect of these
antibodies on either sperm-egg binding or fertilization
in vitro. While such assays are readily available for
some species, researchers are limited in the fox in the
routine use of such assays by both the biology of
foxes and the paucity of an in vitro fertilization assay
system. Because the fox is a seasonal breeder, the
availability of gametes for such studies is restricted to
2 months every year, a fact that severely restricts the
opportunity for assays. There is one reported study of
attempts to establish an in vitro fertilization system for
foxes. But, unfortunately, this procedure is still in the
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early experimental stages, and its routine application
is not feasible at present (Farstad et al. 1993).
An alternative is to test the antifertility effects of
candidate antigen(s) in vivo in female foxes. This
approach is both time consuming and expensive, but it
is highly informative. For example, we have routinely
performed necropsies on the immunized foxes at
about 40 days after mating to evaluate the biological
implications of the immunization regime(s) on fox
reproduction. At the same time, samples of reproductive-tract fluids are collected for assays of the immunoglobulin levels within each section of the tract. This
approach provides information on both the immunology of the treatment and the in vivo effects on fertility.

Do We Use Proteins or Peptides as
Vaccine Antigens?
Ultimately, the choice will have to be made as to
whether a recombinant vaccine for immunocontraception is developed which contains the full target
protein or an antigenic peptide. Decisions will have to
be based on the considerations of the species specificity of the antigen and the ability of any selected
peptide epitope to produce a sufficient immune
response to block fertility. The success of ongoing
research on the selection, design, and construction of
peptide antigens will be vital for the future development of peptide-based vaccines.

lmmune Responses to Gamete
Antigens
Mucosal Immune Response in the
Female Reproductive Tract
The use of a bait-delivered oral immunocontraceptive
for foxes requires a detailed understanding of the
processes involved in the induction, modulation, and
duration of genital tract mucosal immunity. The
immune responses within the female genital tract are
similar to that observed at other mucosal sites.
Vaginal and cervical secretions contain high levels of
immunoglobulin A (IgA) that appear to be locally
synthesized. It has previously been shown that the

reproductive mucosal site is linked to the common
mucosal system and that IgA plasma cells stimulated
at a distant site, such as the gastrointestinal tract, can
rapidly migrate to the female reproductive tract
(McDermott et al. 1980, Parr and Parr 1989 and
1990).
Using a model recombinant-derived antigen,
maltose binding protein (MBP), we have investigated
different immunization regimes to determine which
route induces reproductive-tract mucosal immune
responses within female foxes. Direct administration
of antigen into the Peyers' patches (IPP) has been
used because this route effectively mimics the oral
presentation of an antigen to the gut associated
lymphoid tissue (Dunkley and Husband 1990).
Peyers' patch immunization induces a mucosal
immune response within the female reproductive tract,
but in the absence of a booster immunization, the
antibody responses are transitory, particularly for IgA
(fig. 1). This fact indicates that maintenance of vaginal
IgA antibodies may require the antigen to persist.
To examine this, an experiment was conducted
to test the effect of secondary immunizations with
MBP on the maintenance of vaginal antibody levels.
Three female foxes were immunized IPP and then
boosted intradermally (ID) 1 and 2 months later. The
results show that the levels of both serum and vaginal
antibodies were maintained at higher levels and for
longer compared with foxes receiving a single Peyers'
patch immunization (fig. 2). In light of this information,
female foxes in fertility trials are now routinely immunized IPP followed by a secondary immunization ID,
thus ensuring that high antibodies levels are present
within the reproductive tract throughout the period of
the fertility trial.

lmmune Responses and the Endocrine
System
A number of studies have demonstrated that the sex
hormones estrogen and progesterone can influence
immunoglobulin G (IgG) and IgA antibody production
within the female reproductive tract (McDermott et al.
1980). Any immunocontraceptive vaccine strategy will
have to address the effect that these localized
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changes in the immune status of females may have on
immunocontraception. Effective immunocontraception
will depend on the maintenance of high levels of
antisperm antibodies within the oviducts, uterus, and
vagina during mating. If changes in the localized
antibody concentrations are substantial during this
critical period, then contraception may be compromised (Wira and Sandoe 1987). Studies are under
way in the fox to determine if localized changes are
seen in the reproductive tract IgG and IgA during
estrus.

Long-Term Maintenance of an Immune
Response
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Figure 1. Serum and vaginal fluid antibody responses (Mean + SD;
N = 3) in female foxes as determfned by enzyme-linked
immunosorbent assay (ELISA). Each fox was immunized once
with MBP into four Peyet's patches.
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A problem that may need to be addressed in the
administration of an immunocontraceptive vaccine to
an outbred fox population is the variability of the
immune response between individuals. Effective
application of a vaccine for fertility control requires that
a high level of immunity be achieved among individuals exposed to the vaccine. It may, therefore, be
necessary to include multiple antigenic determinants
within a vaccine to stimulate a broad range of immune
responses. In addition, the antigen(s) may need to be
presented in conjunction with other highly immunogenic carrier proteins to maintain a contraceptive level
of immunity.

Antigen Delivery Systems for a Fox
lmmunocontraceptive Vaccine
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Figure 2. Serum and vaginal fluid antibody responses (Mean + SD;
N = 3) in female foxes as determined by ELISA after immun~zation
with MBP into four Peyer's patches, followed by intradermal
booster mmunizatlons 1 and 2 months later.

At present, three different vaccine delivery systems
are being assessed to determine which will be the
most effective for inclusion into the bait: (1) recombinant derived gamete antigen(s) encapsulated within
microspheres, (2) a recombinant vaccinia virus
capable of expressing foreign antigen(s) in the infected host, and (3) selected recombinant bacterial
vectors such as the attenuated aroA strains of Salrnonella typhirnuriurn.
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Microencapsulated Antigens
The effective oral presentation of antigens to the lower
gastrointestinal tract is hampered by the degradation
of protein within the stomach. A convenient way to
overcome this is to use biodegradable microspheres
that contain the entrapped antigen. These could be
ultimately packaged within a bait, providing an effective oral delivery system whereby the vaccine antigen
is delivered directly to the gut. The microspheres are
taken up by the mucosae with the subsequent induction of a mucosal immune response (McGhee et al.
1992). In recent years, a number of investigators
have reported the successful application of this
technique for the delivery of antigens and the subsequent generation of mucosal immunity to the encapsulated antigens (Mestecky and Eldridge 1991).
We have recently completed a study to evaluate
the efficacy of microspheres containing a recombinant
sperm antigen to stimulate a mucosal immune response in rats (Muir et al. 1994). Microspheres were
synthesized using the poly-DL-lactide-co-glycolide
copolymer incorporating a recombinant source of the
fox sperm protein FSA-1r (Bradley 1994). The oral
administration of FSA-1r-loaded microspheres to rats
resulted in a significant production of cells within the
jejunum that were secreting IgA antibodies specific for
the FSA-l r antigen. The level of stimulation was
comparable to that obtained by either direct immunization of the Peyers' patches with microspheres containing antigen or unencapsulated antigen. These
preliminary results indicate that further experiments
would be worth pursuing to assess the utility of this
approach for antigen delivery to foxes.

Viral Vectors
The use of recombinant vaccinia viral vectors containing the genes encoding selected sperm antigens may
offer an excellent delivery system for an immunocontraceptive vaccine. For example, effective vaccination of foxes with a recombinant vaccinia expressing
the rabies glycoprotein gene has proved enormously
effective for immunizing foxes against rabies (Brochier
et al. 1990). Building on these experiences, we are
developing vaccinia vectors for application in

immunocontraception. Such a system would allow
further studies on the enhancement of the mucosal
immunity, possibly by constructing vectors that
coexpress IgA-specific stimulating cytokines (Ramsay
et al. 1994).
A preliminary assessment of the immunological
responses in foxes to the oral administration of a
recombinant vaccinia viral vector expressing the
hemagglutinin antigen (HA) has begun, and the results
of these experiments will provide a basis for further
experiments designed to test the utility of using a
recombinant poxviruses for the delivery of immunocontraceptive antigens.

Bacterial Vectors
Recombinant bacterial vectors are an alternative
delivery vehicle for a variety of vaccine antigens
(Schodel 1992). The use of attenuated strains of
Salmonella typhimurium as a live vector would be
particularly applicable for stimulating reproductive tract
mucosal immunity because Salmonella sp. colonize
the intestinal tract and proliferate in the gut associated
lymphoid tissue (Curtiss et al. 1989).
The use of selected mutant strains of Salmonella
sp, has the advantage that they can be made avirulent
without decreasing immunogenicity and are not
infective outside the host. These considerations are
important for any recombinant vaccine being considered for environmental release. However, a potential
drawback is that immunity toward the carrier organism
could develop, making subsequent exposure to the
vaccine ineffective.
We have conducted an experiment to assess
whether the attenuated Salmonella typhimurium aroA
mutant strain is capable of stimulating mucosal
immune responses in foxes after oral administration.
Such information is a prerequisite to any future use of
this organism as a vaccine vector. We have found
that foxes given oral doses of Salmonella typhimurium
readily produce serum immunoglobulin M (IgM) and
IgG, and vaginal IgG and IgA antibodies to Salmonella
typhimurium lipopolysaccharide over a 6-week period.
The results indicate that foxes can respond immunologically to a single oral dose of Salmonella
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typhimurium that is sufficient to produce a high and
sustained level of immunity within the female reproductive tract, albeit to a highly immunogenic antigen
(figs. 3 and 4). Experiments are now in progress to
construct a recombinant Salmonella typhimurium
capable of expressing selected sperm antigens. Such
recombinants will be screened for their ability to
induce specific reproductive tract immune responses
to the foreign antigen.
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Fertility control holds exciting prospects for the future
management of wildlife populations. Internationally, a
growing number of scientists and wildlife managers
regard this approach as the only acceptable future
method of managing wildlife populations. However,
the obstacles that will be encountered in the development and implementation of such a technology are
substantial. If the effort is successful, the rewards will
be substantial, too. Each species will yield its own set
of unique challenges.
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Figure 3. Serum IgG and IgM antibody responses (Mean + SD:
N = 2) in female foxes to iipopolysaccharide antigen after one oral
dose of 5 x 1On Salmonella typhimurium (aroA mutant strain
SL3261).
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Figure 4. Vaglnal IgG and IgA antibody responses (Mean SD:
N = 3) in female foxes to iipopolysaccharide antigen after one oral
dose of 5 x 1O~almoneNatyphimurium (aroA mutant strain
SL3261I.
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In this overview, I have summarized key aspects
relating to the reproductive and immunological studies
that are required in the process of developing an
immunocontraceptive vaccine for a vertebrate pest
species. I have attempted to address, albeit in a
rather brief way, the major considerations that need to
be taken in to account when contemplating the development of a fertility control vaccine for wildlife. I have
not considered the wider ecological implications of
fertility control being imposed on a wildlife population.
Such studies pose a whole new set of questions and
challenges, and any project concerned with fertility
control of wildlife will require a large, integral ecology
research program to match the other facets of the
work. Eventually, it will be the ecological studies that
will assess both the impact and long-term consequences of fertility control on a particular wildlife
population.
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